Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Jazz Pharmaceuticals PLC has a consensus price target of $189.2 based on the ratings of 21 analysts. The high is $230 issued by Truist Securities on March 6, 2025. The low is $147 issued by Piper Sandler on May 7, 2025. The 3 most-recent analyst ratings were released by Baird, RBC Capital, and Piper Sandler on May 7, 2025, respectively. With an average price target of $158 between Baird, RBC Capital, and Piper Sandler, there's an implied 47.65% upside for Jazz Pharmaceuticals PLC from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/07/2025 | Buy Now | 44.85% | Baird | Joel Beatty67% | $167 → $155 | Maintains | Outperform | Get Alert |
05/07/2025 | Buy Now | 60.73% | RBC Capital | Gregory Renza49% | $182 → $172 | Maintains | Outperform | Get Alert |
05/07/2025 | Buy Now | 37.37% | Piper Sandler | David Amsellem77% | $176 → $147 | Reiterates | Overweight → Overweight | Get Alert |
05/07/2025 | Buy Now | 55.13% | Morgan Stanley | Jeffrey Hung51% | $183 → $166 | Maintains | Overweight | Get Alert |
05/07/2025 | Buy Now | 86.9% | Needham | Ami Fadia57% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
04/10/2025 | Buy Now | 96.24% | Needham | Ami Fadia57% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
03/10/2025 | Buy Now | 102.78% | HC Wainwright & Co. | Oren Livnat60% | $200 → $217 | Maintains | Buy | Get Alert |
03/07/2025 | Buy Now | 71.01% | Morgan Stanley | Jeffrey Hung51% | $175 → $183 | Assumes | → Overweight | Get Alert |
03/07/2025 | Buy Now | 67.27% | UBS | Ashwani Verma47% | $145 → $179 | Upgrade | Neutral → Buy | Get Alert |
03/06/2025 | Buy Now | 114.93% | Truist Securities | Gregory Fraser63% | $220 → $230 | Maintains | Buy | Get Alert |
03/05/2025 | Buy Now | 96.24% | Needham | Ami Fadia57% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
02/27/2025 | Buy Now | 86.9% | Barclays | Balaji Prasad55% | $190 → $200 | Maintains | Overweight | Get Alert |
02/26/2025 | Buy Now | 40.17% | Cantor Fitzgerald | Charles Duncan69% | $140 → $150 | Downgrade | Overweight → Neutral | Get Alert |
02/26/2025 | Buy Now | 64.47% | Piper Sandler | David Amsellem77% | $163 → $176 | Reiterates | Overweight → Overweight | Get Alert |
02/26/2025 | Buy Now | 66.34% | RBC Capital | Gregory Renza49% | $179 → $178 | Maintains | Outperform | Get Alert |
02/26/2025 | Buy Now | 95.31% | JP Morgan | Jessica Fye67% | $200 → $209 | Maintains | Overweight | Get Alert |
02/26/2025 | Buy Now | 96.24% | Needham | Ami Fadia57% | $205 → $210 | Maintains | Buy | Get Alert |
02/13/2025 | Buy Now | 58.86% | Wells Fargo | Mohit Bansal67% | $130 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
12/12/2024 | Buy Now | 52.32% | Piper Sandler | David Amsellem77% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
12/12/2024 | Buy Now | 67.27% | RBC Capital | Gregory Renza49% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
12/12/2024 | Buy Now | 93.44% | Needham | Ami Fadia57% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
12/10/2024 | Buy Now | 67.27% | RBC Capital | Gregory Renza49% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
11/22/2024 | Buy Now | 86.9% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
11/21/2024 | Buy Now | 93.44% | Needham | Ami Fadia57% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
11/21/2024 | Buy Now | 52.32% | Piper Sandler | David Amsellem77% | $166 → $163 | Reiterates | Overweight → Overweight | Get Alert |
11/18/2024 | Buy Now | 51.39% | Baird | Joel Beatty67% | $154 → $162 | Maintains | Outperform | Get Alert |
11/07/2024 | Buy Now | 82.23% | TD Cowen | — | $200 → $195 | Maintains | Buy | Get Alert |
11/07/2024 | Buy Now | 93.44% | Needham | Ami Fadia57% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
10/23/2024 | Buy Now | 67.27% | RBC Capital | Gregory Renza49% | $175 → $179 | Maintains | Outperform | Get Alert |
10/04/2024 | Buy Now | 63.54% | RBC Capital | Gregory Renza49% | $174 → $175 | Maintains | Outperform | Get Alert |
09/10/2024 | Buy Now | 91.57% | Needham | Ami Fadia57% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
09/09/2024 | Buy Now | 30.83% | Cantor Fitzgerald | Charles Duncan69% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
08/19/2024 | Buy Now | 88.77% | JP Morgan | Jessica Fye67% | $190 → $202 | Maintains | Overweight | Get Alert |
08/01/2024 | Buy Now | 30.83% | Cantor Fitzgerald | Charles Duncan69% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
08/01/2024 | Buy Now | 55.13% | Piper Sandler | David Amsellem77% | $188 → $166 | Maintains | Overweight | Get Alert |
08/01/2024 | Buy Now | 62.6% | RBC Capital | Gregory Renza49% | $175 → $174 | Maintains | Outperform | Get Alert |
08/01/2024 | Buy Now | 12.14% | Wells Fargo | Mohit Bansal67% | $140 → $120 | Maintains | Equal-Weight | Get Alert |
08/01/2024 | Buy Now | 91.57% | Needham | Ami Fadia57% | $208 → $205 | Maintains | Buy | Get Alert |
08/01/2024 | Buy Now | 86.9% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
08/01/2024 | Buy Now | 43.91% | Baird | Joel Beatty67% | $160 → $154 | Maintains | Outperform | Get Alert |
07/12/2024 | Buy Now | 40.17% | Morgan Stanley | Jeffrey Hung51% | $160 → $150 | Maintains | Equal-Weight | Get Alert |
07/02/2024 | Buy Now | 5.6% | UBS | Ashwani Verma47% | $117 → $113 | Maintains | Neutral | Get Alert |
06/20/2024 | Buy Now | 96.24% | Needham | Ami Fadia57% | $222 → $210 | Maintains | Buy | Get Alert |
06/05/2024 | Buy Now | 57.93% | Goldman Sachs | Madhu Kumar72% | → $169 | Initiates | → Buy | Get Alert |
05/03/2024 | Buy Now | 86.9% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
05/03/2024 | Buy Now | 86.9% | Barclays | Balaji Prasad55% | $230 → $200 | Maintains | Overweight | Get Alert |
05/02/2024 | Buy Now | 107.46% | Needham | Ami Fadia57% | $222 → $222 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | Buy Now | 68.21% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
03/22/2024 | Buy Now | 68.21% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
03/22/2024 | Buy Now | 77.55% | JP Morgan | Jessica Fye67% | $170 → $190 | Maintains | Overweight | Get Alert |
03/20/2024 | Buy Now | 105.59% | Needham | Ami Fadia57% | $220 → $220 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | Buy Now | 86.9% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | Buy Now | 75.68% | Piper Sandler | David Amsellem77% | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
03/15/2024 | Buy Now | 114.93% | Stifel | Annabel Samimy66% | $225 → $230 | Maintains | Buy | Get Alert |
03/14/2024 | Buy Now | 86.9% | HC Wainwright & Co. | Oren Livnat60% | $204 → $200 | Maintains | Buy | Get Alert |
03/01/2024 | Buy Now | 114.93% | Barclays | Balaji Prasad55% | $235 → $230 | Maintains | Overweight | Get Alert |
03/01/2024 | Buy Now | 22.42% | UBS | Ashwani Verma47% | $135 → $131 | Maintains | Neutral | Get Alert |
02/29/2024 | Buy Now | 82.23% | RBC Capital | Gregory Renza49% | $195 → $195 | Reiterates | Outperform → Outperform | Get Alert |
02/29/2024 | Buy Now | 68.21% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
02/29/2024 | Buy Now | 58.86% | JP Morgan | Jessica Fye67% | $180 → $170 | Maintains | Overweight | Get Alert |
02/29/2024 | Buy Now | 105.59% | Needham | Ami Fadia57% | $225 → $220 | Maintains | Buy | Get Alert |
01/29/2024 | Buy Now | 119.61% | Barclays | Balaji Prasad55% | $240 → $235 | Maintains | Overweight | Get Alert |
01/03/2024 | Buy Now | 49.52% | Baird | Joel Beatty67% | → $160 | Initiates | → Outperform | Get Alert |
12/04/2023 | Buy Now | 86.9% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | Buy Now | 110.26% | Needham | Ami Fadia57% | → $225 | Reiterates | Buy → Buy | Get Alert |
11/27/2023 | Buy Now | 26.16% | UBS | Ashwani Verma47% | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
11/09/2023 | Buy Now | 78.49% | RBC Capital | Gregory Renza49% | $200 → $191 | Maintains | Outperform | Get Alert |
11/09/2023 | Buy Now | 110.26% | Needham | Ami Fadia57% | $226 → $225 | Maintains | Buy | Get Alert |
09/29/2023 | Buy Now | — | Raymond James | Gary Nachman58% | — | Initiates | → Market Perform | Get Alert |
08/22/2023 | Buy Now | 68.21% | Cantor Fitzgerald | Brandon Folkes40% | → $180 | Reiterates | Overweight → Overweight | Get Alert |
08/14/2023 | Buy Now | 68.21% | Cantor Fitzgerald | Brandon Folkes40% | $210 → $180 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 90.64% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | Buy → Buy | Get Alert |
08/10/2023 | Buy Now | 102.78% | B of A Securities | Jason Gerberry59% | $204 → $217 | Maintains | Buy | Get Alert |
08/10/2023 | Buy Now | 87.83% | RBC Capital | Gregory Renza49% | $203 → $201 | Maintains | Outperform | Get Alert |
08/10/2023 | Buy Now | 111.2% | Needham | Ami Fadia57% | → $226 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | Buy Now | 111.2% | Needham | Ami Fadia57% | → $226 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | Buy Now | 74.75% | Morgan Stanley | Jeffrey Hung51% | $187 → $187 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
06/05/2023 | Buy Now | 111.2% | Needham | Ami Fadia57% | → $226 | Reiterates | Buy → Buy | Get Alert |
05/30/2023 | Buy Now | 111.2% | Needham | Ami Fadia57% | $212 → $226 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | Buy Now | 90.64% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | Buy Now | 98.11% | Needham | Ami Fadia57% | → $212 | Reiterates | Buy → Buy | Get Alert |
05/11/2023 | Buy Now | 88.77% | RBC Capital | Gregory Renza49% | $207 → $202 | Maintains | Outperform | Get Alert |
05/11/2023 | Buy Now | 98.11% | Needham | Ami Fadia57% | $205 → $212 | Maintains | Buy | Get Alert |
03/06/2023 | Buy Now | 90.64% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | → Buy | Get Alert |
03/03/2023 | Buy Now | 98.11% | Goldman Sachs | Madhu Kumar72% | $190 → $212 | Maintains | Buy | Get Alert |
03/02/2023 | Buy Now | 91.57% | Needham | Ami Fadia57% | $210 → $205 | Maintains | Buy | Get Alert |
12/09/2022 | Buy Now | 77.55% | Goldman Sachs | Madhu Kumar72% | $192 → $190 | Upgrade | Neutral → Buy | Get Alert |
11/10/2022 | Buy Now | 79.42% | Goldman Sachs | Madhu Kumar72% | $170 → $192 | Maintains | Neutral | Get Alert |
11/10/2022 | Buy Now | 93.44% | RBC Capital | Gregory Renza49% | $206 → $207 | Maintains | Outperform | Get Alert |
11/10/2022 | Buy Now | 94.37% | Needham | Ami Fadia57% | $210 → $208 | Maintains | Buy | Get Alert |
09/29/2022 | Buy Now | 58.86% | Goldman Sachs | Madhu Kumar72% | $148 → $170 | Maintains | Neutral | Get Alert |
09/21/2022 | Buy Now | 38.3% | Goldman Sachs | Madhu Kumar72% | $192 → $148 | Maintains | Neutral | Get Alert |
08/04/2022 | Buy Now | 75.68% | BMO Capital | Gary Nachman58% | $185 → $188 | Maintains | Outperform | Get Alert |
08/04/2022 | Buy Now | 74.75% | Morgan Stanley | Jeffrey Hung51% | $174 → $187 | Maintains | Equal-Weight | Get Alert |
08/04/2022 | Buy Now | 78.49% | UBS | Ashwani Verma47% | $194 → $191 | Maintains | Buy | Get Alert |
08/04/2022 | Buy Now | 96.24% | SVB Leerink | Marc Goodman73% | $200 → $210 | Maintains | Outperform | Get Alert |
06/14/2022 | Buy Now | 81.29% | UBS | Ashwani Verma47% | → $194 | Initiates | → Buy | Get Alert |
The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Baird on May 7, 2025. The analyst firm set a price target for $155.00 expecting JAZZ to rise to within 12 months (a possible 44.85% upside). 44 analyst firms have reported ratings in the last year.
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Baird, and Jazz Pharmaceuticals maintained their outperform rating.
The last upgrade for Jazz Pharmaceuticals PLC happened on March 7, 2025 when UBS raised their price target to $179. UBS previously had a neutral for Jazz Pharmaceuticals PLC.
The last downgrade for Jazz Pharmaceuticals PLC happened on February 26, 2025 when Cantor Fitzgerald changed their price target from $140 to $150 for Jazz Pharmaceuticals PLC.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $167.00 to $155.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $107.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.